0000000001168957

AUTHOR

G Tognoni

showing 3 related works from this author

Large-scale gene-centric analysis identifies novel variants for coronary artery disease.

2011

Coronary artery disease (CAD) has a significant genetic contribution that is incompletely characterized. To complement genome-wide association (GWA) studies, we conducted a large and systematic candidate gene study of CAD susceptibility, including analysis of many uncommon and functional variants. We examined 49,094 genetic variants in ∼2,100 genes of cardiovascular relevance, using a customised gene array in 15,596 CAD cases and 34,992 controls (11,202 cases and 30,733 controls of European descent; 4,394 cases and 4,259 controls of South Asian origin). We attempted to replicate putative novel associations in an additional 17,121 CAD cases and 40,473 controls. Potential mechanisms through w…

MaleCancer ResearchCandidate geneEpidemiologyGenome-wide association studyCoronary Artery Disease030204 cardiovascular system & hematologyCardiovascular0302 clinical medicineGENETICS & HEREDITYGenetics (clinical)Genetics0303 health sciencesCardiovascular diseases [NCEBP 14]Middle Aged3. Good healthCYP17A1Genetic EpidemiologyGenome-wide association; Myocardial-infarction; Susceptibility loci; Risk; Atherosclerosis; Metanalysis; LipoproteinMedicineFemaleLife Sciences & BiomedicineResearch ArticleAsian Continental Ancestry GroupAdultRiskSUSCEPTIBILITY LOCIlcsh:QH426-470European Continental Ancestry GroupBiologyPolymorphism Single Nucleotidecoronary artery disease; geneticsWhite People03 medical and health sciencesSDG 3 - Good Health and Well-beingAsian PeopleGenetic variationGeneticsHumansGenetic Predisposition to DiseaseGENOME-WIDE ASSOCIATIONAlleleMolecular BiologyGeneBiologyMETAANALYSISEcology Evolution Behavior and SystematicsGenetic Association StudiesCardiovascular Disease EpidemiologyAlleles030304 developmental biologyAged0604 GeneticsScience & TechnologyCase-control studyGenetic VariationHuman GeneticsOdds ratiolarge-scale gene analysiscoronary artery disease; large-scale gene analysislcsh:GeneticsLIPOPROTEINMYOCARDIAL-INFARCTIONATHEROSCLEROSISCase-Control StudiesGenetics of DiseaseIBC 50K CAD ConsortiumDevelopmental BiologyGenome-Wide Association Study
researchProduct

When the amnestic mild cognitive impairment disappears: characterisation of the memory profile

2009

BACKGROUND/OBJECTIVES: Subjects affected by mild cognitive impairment (MCI) may improve during the observation period. This is the first study investigating qualitative features of memory deficits in subjects affected by reversible MCI [reversible cognitive impairment (RCI)]. METHODS: Baseline cognitive and memory performances of 18 subjects affected by amnestic MCI who had normalized cognitive performances at follow-ups were compared with those of 76 amnestic MCI subjects who still showed impaired cognitive performances at the 24-month follow-up (MCI) and with those of a group of 87 matched control subjects (normal controls). RESULTS: Compared with normal controls the memory deficit in the…

MalememorianeuropsychologyAudiologyNeuropsychological TestsAlzheimer diseaseMemoryMild cognitive impairmentNeuropsychologyPreclinical dementiadeterioramento cognitivo lieveLong-term memoryCognitive disorderNeuropsychologypreclinical dementiaCognitionGeneral MedicinePsychiatry and Mental healthNeuropsychology and Physiological PsychologyMemory Short-TermDisease ProgressionFemaleSettore MED/26 - Neurologiamedicine.symptomAlzheimer's diseasePsychologymedicine.medical_specialtyCognitive NeuroscienceAmnesiaHumans; Alzheimer Disease; Disease Progression; Aged; Mental Recall; Cognition Disorders; Memory; Memory Short-Term; Recognition (Psychology); Psychomotor Performance; Follow-Up Studies; Neuropsychological Tests; Amnesia; Female; MaleRecognition (Psychology)M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICAbehavioral disciplines and activitiesmild cognitive impairmentAlzheimer DiseaseMemorymental disordersNeuropsychologiamedicineHumansMemory disorderAgedMED/26 - NEUROLOGIARecognition Psychologymedicine.diseaseMCInervous system diseasesShort-TermMental Recallmild cognitive impairment; neuropsychology; memory; preclinical dementia; Alzheimer diseaseAmnesiaMED/09 - MEDICINA INTERNACognition Disordershuman activitiesNeurosciencePsychomotor PerformanceFollow-Up Studies
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct